First National Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

First National Advisers’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-163	Closed	-$112K	–	126
2022 Q3	$112K	Buy	+163	New	+$103K	0.17%	118

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

First National Advisers's REGN Position: Q4 2022 in Review

First National Advisers sold out of Regeneron Pharmaceuticals (REGN) in Q4 2022, closing a stake of 163 shares — an estimated $112K sold.

First National Advisers first reported a position in REGN in Q3 2022 and held it in 1 quarter. The position peaked at $112K in Q3 2022. 1,158 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

First National Advisers reported no remaining Regeneron Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
First National Advisers sold 163 Regeneron Pharmaceuticals shares in Q4 2022, an estimated $112K.
First National Advisers first reported a position in Regeneron Pharmaceuticals in Q3 2022 and held it in 1 quarter.
First National Advisers's Regeneron Pharmaceuticals position peaked at $112K in Q3 2022.
1,158 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on First National Advisers's 13F filing for Q4 2022, filed 9 Feb 2023.